Preoperative surgeon evaluation of corneal endothelial status: the Viability Control of Human Endothelial Cells before Keratoplasty (V-CHECK) study protocol.
Cornea
Treatment Surgery
Journal
BMJ open ophthalmology
ISSN: 2397-3269
Titre abrégé: BMJ Open Ophthalmol
Pays: England
ID NLM: 101714806
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
21
06
2023
accepted:
31
08
2023
medline:
22
9
2023
pubmed:
21
9
2023
entrez:
20
9
2023
Statut:
ppublish
Résumé
The success of keratoplasty strongly depends on the health status of the transplanted endothelial cells. Donor corneal tissues are routinely screened for endothelial damage before shipment; however, surgical teams have currently no means of assessing the overall viability of corneal endothelium immediately prior to transplantation. The aim of this study is to validate a preoperative method of evaluating the endothelial health of donor corneal tissues, to assess the proportion of tissues deemed suitable for transplantation by the surgeons and to prospectively record the clinical outcomes of a cohort of patients undergoing keratoplasty in relation to preoperatively defined endothelial viability. In this multicentre cohort study, consecutive patients undergoing keratoplasty (perforating keratoplasty, Descemet stripping automated endothelial keratoplasty (DSAEK), ultra-thin DSAEK (UT-DSAEK) or Descemet membrane endothelial keratoplasty) will be enrolled and followed-up for 1 year. Before transplantation, the endothelial viability of the donor corneal tissue will be evaluated preoperatively through trypan blue staining and custom image analysis to estimate the overall percentage of trypan blue-positive areas (TBPAs), a proxy of endothelial damage. Functional and structural outcomes at the end of the follow-up will be correlated with preoperatively assessed TBPA values. The protocol will be reviewed by the ethical committees of participating centres, with the sponsor centre issuing the final definitive approval. The results will be disseminated on ClinicalTrials.gov, at national and international conferences, by partner patient groups and in open access, peer-reviewed journals. NCT05847387.
Identifiants
pubmed: 37730252
pii: bmjophth-2023-001361
doi: 10.1136/bmjophth-2023-001361
pmc: PMC10510883
pii:
doi:
Substances chimiques
Trypan Blue
I2ZWO3LS3M
Banques de données
ClinicalTrials.gov
['NCT05847387']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: YZ, SK and VR are editors of BMJ Open Ophthalmology.
Références
Int J Biostat. 2016 Nov 1;12(2):
pubmed: 27838682
Transplantation. 2008 Dec 27;86(12):1720-4
pubmed: 19104411
Ophthalmology. 2013 Dec;120(12):2428-2435
pubmed: 24246826
Am J Ophthalmol. 2021 Apr;224:254-266
pubmed: 33129808
JAMA Ophthalmol. 2015 Nov;133(11):1277-85
pubmed: 26355238
Invest Ophthalmol Vis Sci. 2014 Nov 25;55(12):8409-15
pubmed: 25425307
JAMA Ophthalmol. 2015 Nov;133(11):1285-6
pubmed: 26356492
JAMA Ophthalmol. 2015 Mar;133(3):246-54
pubmed: 25322173
PLoS One. 2017 Sep 13;12(9):e0184375
pubmed: 28902856
Arch Ophthalmol. 2004 May;122(5):736-42
pubmed: 15136322
Br J Ophthalmol. 2022 Feb;106(2):177-183
pubmed: 33127828
Br J Ophthalmol. 2016 Apr;100(4):572-8
pubmed: 26740609
Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):6018-25
pubmed: 21666243